Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Increased Interoperability in ePrescribing Can Elevate Patient Safety

In these times of pandemic certainty and as the future of healthcare beyond COVID-19 begins to take shape, elevating patient safety has never been more important  Access to prescriptions is crucial to the health and success of patients, and electronic prescribing (ePrescribing) allows prescribers and pharmacies to prescribe medications virtually. “With electronic prescribing, or ‘e-prescribing,’ health care…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
How Increased Interoperability in ePrescribing Can Elevate Patient Safety

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In these times of pandemic certainty and as the future of healthcare beyond COVID-19 begins to take shape, elevating patient safety has never been more important Access to prescriptions is crucial to the health and success of patients, and electronic prescribing (ePrescribing) allows prescribers and pharmacies to prescribe medications virtually.

“With electronic prescribing, or ‘e-prescribing,’ health care providers can enter prescription information into a computer device – like a tablet, laptop, or desktop computer – and securely transmit the prescription to pharmacies using a special software program and connectivity to a transmission network,” according to The Office of the National Coordinator for Health Information Technology (ONC).

Though ePrescribing is a convenient and affordable method of prescribing medications, it’s not without its risks – and increased interoperability is needed to address those risks.

Boosting Interoperability to Reduce Prescription Drug Errors and More

For ePrescribing services to be as safe as possible, providers and pharmacies need to have access to up-to-date interoperability methods to increase accuracy of patient data and drug usage.

With technology rapidly growing and 2020 bringing healthcare to the forefront, it is sensible that, without technological change, servers will not be able to efficiently organize patient data. EPrescribing takes previous challenges of accurate data and drug usage and relies on new technology to adjust the results.

Research has shown in increased need to reliable prescription information. EHR Intelligence reported that, “researchers audited a random 65 failed prescriptions and found 39 were the result of a mismatched national drug code (NDC). Seventeen failures did not find the targeting prescriber because the prescriber did not have a profile in the platform. The remaining nine failures could not find the targeted patient because the patient did not have a profile on the platform.”

Making the Most of the Benefits of ePrescribing

The benefits of ePrescribing include empowering long-term care facilities to safely care for patients, allowing prescribers to effectively communicate with pharmacies to fulfill requests, and ensuring providers can safely administer controlled substances.

The DEA’s EPCS regulation, 21 CFR §1311, requires additional security considerations that ensure the prescriber is authentic and has the necessary certification. In the long run, this could also help reduce some of the wide-spread opioid crisis that United States is facing.

Although ePrescribing adoption has started to accelerate, uptake is not where policymakers want it to be. Levels of ePrescribing use have been lower than expected among those who have adopted the technology. Some barriers of use include a lack of knowledge with integrating new technology. There are more than 100 commercial ePrescribing systems available today, many of which do not have the full set of functionalities required for ePrescribing in Medicare Part D or MIPPA.

Increasing industry collaboration is going to be necessary in order to fully integrate this new way of prescribing. Adaptive policy makers and healthcare business models are crucial in next steps to ensuring a safe drug-prescribing world.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512